Teva Pharmaceutical Industries LimitedOpportunity Rank #272(TEVA) Intrinsic Value & DCF Analysis (2026)
Current Price
$31.18
Last updated: Jul 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
As of 2026-07-24
Still researching stocks one at a time?
Intrinziq helps you:
- Turn your stock-picking rules into repeatable strategies
- Find better setups across hundreds of stocks automatically
- Backtest your strategy before putting money to work
The intrinsic value of Teva Pharmaceutical Industries Limited (TEVA) is estimated at $5.68 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $31.18, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -5.56% long-term growth rate and a 9.00% discount rate (calculated: 7.58%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of Teva Pharmaceutical Industries Limited (TEVA) is estimated at $5.68 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $31.18, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -5.56% long-term growth rate and a 9.00% discount rate (calculated: 7.58%), reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Price moves to at least a mid-teens discount to fair value
- Sustained improvement in ROIC versus WACC spread
- Meaningful shifts in the narrative score direction
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Teva Pharmaceutical Industries Limited's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Teva Pharmaceutical Industries LimitedHealthcare
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.